Issued 2026-08-13 at $13.71 · now $17.35 (2026-08-13, +26.5% since)
Based on its own history, a month from the 2026-08-13 close, OMER has typically landed between $8.75 and $23.92 — a range of −36.1% to +74.5% from the issuance price $13.71.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,209 overlapping 1 month windows · 2009-10-08 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($13.71) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where OMER has typically landed a month from the 2026-08-13 close of $13.71 — the range is history, not a prediction.
- now $17.35 (+26.5%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $13.55 (-1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.95–$16.14
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $8.75–$23.92
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2021-09-17 | −64.5% | −64.5% | +0.0% |
| 2023-09-28 | −63.0% | −63.0% | +0.0% |
| 2023-09-22 | −61.9% | −61.9% | +1.7% |
| 3 best | |||
| 2024-10-25 | +190.0% | −3.6% | +190.0% |
| 2024-11-01 | +186.3% | +0.0% | +197.8% |
| 2024-10-30 | +183.2% | −4.3% | +187.9% |
4,209 overlapping windows · 2009-10-08 – 2026-08-13 · not cherry-picked
Pending catalysts
- December 2026 — Trial primary completion: Phase 2 primary completion: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~17 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.